Technical Analysis for IBRX - ImmunityBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -0.79% | |
| MACD Bearish Centerline Cross | Bearish | -0.79% | |
| NR7 | Range Contraction | -0.79% | |
| Down 3 Days in a Row | Weakness | -0.79% | |
| Down 4 Days in a Row | Weakness | -0.79% | |
| 20 DMA Support | Bullish | -4.13% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 6 hours ago |
| 20 DMA Resistance | about 6 hours ago |
| 10 DMA Resistance | about 6 hours ago |
| Up 5% | about 6 hours ago |
| Up 3% | about 6 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/06/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Average Volume | 7,891,167 |
| 200-Day Moving Average | 4.58 |
| 50-Day Moving Average | 6.88 |
| 20-Day Moving Average | 6.34 |
| 10-Day Moving Average | 6.63 |
| Average True Range | 0.55 |
| RSI (14) | 45.65 |
| ADX | 14.67 |
| +DI | 24.96 |
| -DI | 21.47 |
| Chandelier Exit (Long, 3 ATRs) | 5.98 |
| Chandelier Exit (Short, 3 ATRs) | 7.14 |
| Upper Bollinger Bands | 7.29 |
| Lower Bollinger Band | 5.40 |
| Percent B (%b) | 0.46 |
| BandWidth | 29.85 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0318 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.89 | ||||
| Resistance 3 (R3) | 6.94 | 6.80 | 6.78 | ||
| Resistance 2 (R2) | 6.80 | 6.64 | 6.77 | 6.75 | |
| Resistance 1 (R1) | 6.53 | 6.54 | 6.46 | 6.48 | 6.71 |
| Pivot Point | 6.39 | 6.39 | 6.35 | 6.36 | 6.39 |
| Support 1 (S1) | 6.12 | 6.23 | 6.05 | 6.07 | 5.83 |
| Support 2 (S2) | 5.98 | 6.13 | 5.95 | 5.79 | |
| Support 3 (S3) | 5.71 | 5.98 | 5.76 | ||
| Support 4 (S4) | 5.66 |
